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Abstract Arsenic trioxide has been successfully used as a
therapeutic in the treatment of acute promyelocytic leuke-
mia (APL). Detailed monitoring of the therapeutic arsenic
and its metabolites in various accessible specimens of APL
patients can contribute to improving treatment efficacy and
minimizing arsenic-induced side effects. This article focuses
on the determination of arsenic species in saliva samples
from APL patients undergoing arsenic treatment. Saliva sam-
ples were collected from nine APL patients over three consec-
utive days. The patients received 10 mg arsenic trioxide each
day via intravenous infusion. The saliva samples were analyzed
using high-performance liquid chromatography coupled with
inductively coupled plasma mass spectrometry. Monomethy-
larsonous acid and monomethylmonothioarsonic acid were
identified along with arsenite, dimethylarsinic acid, monome-
thylarsonic acid, and arsenate. Arsenite was the predominant
arsenic species, accounting for 71.8 % of total arsenic in the
saliva. Following the arsenic infusion each day, the percentage
of methylated arsenicals significantly decreased, possibly sug-
gesting that the arsenic methylation process was saturated by
the high doses immediately after the arsenic infusion. The
temporal profiles of arsenic species in saliva following each
arsenic infusion over 3 days have provided information on
arsenic exposure, metabolism, and excretion. These results
suggest that saliva can be used as an appropriate clinical bio-
marker for monitoring arsenic species in APL patients.
Keywords Acute promyelocytic leukemia . Arsenic
speciation . Saliva . Metabolism . Arsenic trioxide treatment
Introduction
Acute promyelocytic leukemia (APL) is a distinctive subtype
of acute myelocytic leukemia characterized by reciprocal
translocations between chromosomes 15 and 17. Many clini-
cal trials have demonstrated that both new and relapsed APL
patients can achieve complete remission after arsenic trioxide
treatment [1–7]. Generally, APL patients receive intravenous
infusions of an aqueous solution of inorganic arsenic over the
course of 2–5 h [1, 2, 4, 7]. In spite of the good efficacy of
arsenic treatment, fatalities of APL patients and arsenic-
induced side effects, e.g., skin and gastrointestinal reactions,
liver and cardiac dysfunction, and neuropathy, have also been
reported [2, 4, 7–9]. With the aim of alleviating side effects
and maximizing treatment efficacy, extensive efforts have
been made to elucidate the mechanisms of action, such as
the effects of arsenic on apoptosis, differentiation, degradation
of oncogenic fusion proteins, and signal transduction [10–14],
as well as metabolism of arsenic in APL patients [15–17].
Inorganic arsenic can be readily transformed in many
organisms through a biological process consisting of alternat-
ing reduction and oxidative methylation reactions, which con-
sequently leads to the formation of various arsenic metabolites
[15, 18–22]. Monomethylarsonic acid (MMAV) and dimethy-
larsinic acid (DMAV) have commonly been detected in human
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urine, saliva, and blood [15, 16, 20–26]. However, monome-
thylarsonous acid (MMAIII) and dimethylarsinous acid
(DMAIII), which are proposed as important intermediates in
the transformation process of inorganic arsenic, have been
detected only in human urine [15, 27–29]. Recently, thiolated
methylated arsenicals have also been identified as metabolites
of inorganic arsenic in human urine [30, 31].
Various arsenic metabolites exhibit differing toxicities.
For instance, trivalent methylated arsenicals are more toxic
than their pentavalent counterparts [12, 32–35], and the
toxicities of thiolated arsenicals are greater than those of
pentavalent oxygen-containing analogs [30, 36–38]. Owing
to the extreme variations in the toxicity of arsenic metabo-
lites, it is necessary to identify and quantify arsenic species
in APL patients undergoing arsenic treatment. The specia-
tion information will contribute to improve our understand-
ing of arsenic metabolism and to the design of timely
clinical intervention and personalized therapy.
Although previous studies have determined arsenicals in
the urine and blood of APL patients undergoing arsenic treat-
ment [15–17], arsenic speciation in the saliva of APL patients
has not been reported. Salivary glands have high blood flows,
and arsenic species in the blood could be distributed to saliva.
Collection of saliva samples is noninvasive and readily
achievable. Thus, determination of arsenic species in saliva
can complement biomonitoring of arsenic species in urine and
blood, serving as a potential biomarker for assessment of
recent exposure. The primary objective of this work is to
identify and quantify arsenic species in saliva samples from
APL patients undergoing arsenic treatment. Achieving this
objective involves the development of arsenic speciation anal-
ysis and the application of this technique to determining
temporal profiles of arsenic species in saliva.
Materials and methods
Reagents
MMAIII and DMAIII were synthesized in the iodide form of
CH3AsI2 and (CH3)2AsI according to the literature [39], and
were kept at 4 and −20 °C, respectively. Monomethylmo-
nothioarsonic acid (MMMTAV) and dimethylmonothioar-
sinic acid (DMMTAV) were prepared according to a
reported method [40], and were stored at −20 °C. Their
stock solutions were freshly prepared in deionized water.
Stock solutions of other standards (1,000 mg/L as arsenic)
were prepared by dissolving appropriate amounts of AsIII,
AsV, DMAV (all from Aldrich), and MMAV (Chem Service)
in deionized water. Their working solutions were prepared
daily by serial dilutions in deionized water.
Tetrabutylammonium hydroxide (Aldrich), malonic acid
(Aldrich), and high-performance liquid chromatography
(HPLC) grade methanol (Fisher) were used for preparing
the mobile phase. The mobile phase was filtered through a
0.45-μm membrane filter.
A certified reference material (“Toxic Metals in Freeze-
Dried Human Urine,” certified reference material no. 18
from the National Institute for Environmental Studies, Japan
Environment Agency) was used for quality control purpo-
ses. This certified reference material was reconstituted by
dissolving it in 20.0 mL deionized water according to the
instructions provided by the supplier. The certified value for
DMAV was 36±9 μg/L.
APL patients and sample collection
Saliva samples were collected from nine patients who were
undergoing arsenic treatment at Harbin Medical University
Hospital. Informed consent was acquired from each patient
prior to the study, which was conducted in compliance with
the guidelines and regulations of the ethical review boards
of the University of Alberta and Harbin Medical University
Hospital (200816). Demographic information on the APL
patients is given in Table 1. Two relapsed patients were
returning for arsenic treatment, and the other patients were
newly diagnosed with APL. Before the start of sample
collection, two patients (one returning and one new) did
not receive arsenic treatment, whereas the other patients
had been treated with arsenic for differing durations, as
shown in Table 1.
Ten milligrams of As2O3 (Yida Pharmaceutical, Harbin,
China) dissolved in a 10-mL aqueous solution was added to
500 mL of 5 % glucose normal saline solution for intrave-
nous infusion. The infusion usually takes 2–4 h. Arsenic
was administered to patients 4, 5, and 9 over a period as
long as 18 h because it caused them serious side effects.
White blood cell counts and routine blood analysis were
performed to monitor the health of APL patients. One saliva
Table 1 Demographic information on acute promyelocytic leukemia









1 F 29 Relapsed 0
2 F 36 Relapsed 4
3 F 19 New 54
4 F 24 New 0
5 F 24 New 13
6 M 30 New 11
7 F 40 New 9
8 M 50 New 44
9 F 52 New 16
F female, M male
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sample was collected from each patient immediately prior to
daily infusion of arsenic. All patients then received intrave-
nous infusions of the same dose of AsIII (10 mg As2O3), and
saliva samples were collected consecutively in the subse-
quent 24 h before the next infusion. Sample collection was
repeated for two or three 24-h cycles following different
AsIII infusions. In total, 108 saliva samples were collected
from nine APL patients. APL patients were required to rinse
their mouths thoroughly with deionized water three times
before saliva sampling; then they spat saliva samples direct-
ly into 15-mL polyethylene centrifuge tubes. Immediately
after sample collection, saliva samples were divided into
three 1-mL aliquots in 1.5-mL vials. The vials were sealed
with Parafilm and transported on dry ice. The samples were
stored at −20 °C until arsenic speciation analysis.
Pretreatment of saliva for arsenic speciation analysis
The method of pretreatment of saliva for arsenic speciation
analysis has been described in the literature [23]. In brief,
frozen saliva samples were thawed at room temperature and
thoroughly vortex-mixed. A 0.5-mL aliquot of saliva sam-
ples was diluted three times with deionized water in a 15-
mL centrifuge tube, and thoroughly vortex-mixed again.
The diluted saliva samples were sonicated for 30 min, and
then filtered through a 0.45-μm membrane filter prior to
arsenic speciation analysis.
Identification and quantification of arsenic species by HPLC–
inductively coupled plasma mass spectrometry
An Agilent 1100 series HPLC system consisting of a pump,
degasser, autosampler, column temperature control, and
reversed-phase C18 column (ODS-3, 150 mm×4.6 mm,
3-μm particle size; Phenomenex, Torrance, CA, USA) was
used for the separation of arsenicals. An octadecylsilane
guard cartridge (4 mm×3 mm) was mounted before the
analytical column. The mobile phase consisted of 5 mM
tetrabutylammonium, 5 % methanol, and 3 mM malonic
acid (pH 5.65). The column was equilibrated with the mo-
bile phase for at least 0.5 h at a flow rate of 0.8 mL/min
before sample injection. A 50-μL aliquot of pretreated sali-
va samples was injected and separation was performed at a
flow rate of 1.2 mL/min; the column temperature was main-
tained at 50 °C.
The effluent from HPLC was introduced directly into the
nebulizer of a 7500ce inductively coupled plasma (ICP)
mass spectrometry (MS) instrument (Agilent Technologies,
Japan) using PEEK tubing. The collision cell of the ICP MS
instrument was operated in helium mode. Helium
(3.5 mL/min) was used in the octopole reaction cell to
reduce isobaric and polyatomic interferences. The ICP op-
erated at a radio-frequency power of 1,550 W, and the flow
rate of argon carrier gas was 0.9–1.0 L/min. Arsenic was
monitored at m/z 75. Chromatograms from HPLC separation
were recorded by ICP-MS ChemStation (Agilent Technolo-
gies, Santa Clara, CA, USA).
Identification of MMMTAV by HPLC–electrospray
ionization tandem mass spectrometry
For optimization of operating conditions, 1–5 μMMMMTAV
in a solution of methanol and water (1:1, v/v) was infused into
a triple-quadrupole mass spectrometer (5000 QTRAP, MDS
SCIEX, Concord, ON, Canada) equipped with an electrospray
ion source. The electrospray ionization (ESI) tandem mass
spectrometry (MS/MS) instrument was operated in negative
ionization mode. The characteristic multiple reaction monitor-
ing transitions of MMMTAV were 155/107, 155/121, and
155/137. The optimal parameters were as follows: IonSpray
voltage −4,500 V, interface temperature 200 °C, curtain gas
flow rate 10 L/min, and declustering potential −75 V. The
collision energy and the cell exit potential were −34 and
−13 V for 155/107, -22 and −11 V for 155/121, and −22
and −11 V for 155/137.
The ESI-MS/MS instrument was coupled with an 1100
series HPLC system (Agilent, Santa Clara, CA, USA)
equipped with a quaternary pump, degasser, column tem-
perature control, and temperature-controlled autosampler.
An anion-exchange column (PRP-X100, 50 mm×4.6 mm,
10 μm; Hamilton, Reno, NV, USA) was used for separation,
with the mobile phase comprising 50 % methanol and 5 mM
ammonium formate (pH 6) at a flow rate of 1 mL/min. The
temperature of the autosampler was kept at 4 °C, and the
injection volume was 50 μL.
Results
Trivalent and thiolated monomethylated arsenicals, MMAIII
and MMMTAV
Separation of eight arsenicals—AsIII, MMAIII, DMAV,
MMAV, AsV, DMMTAV, DMAIII, and MMMTAV—was
achieved using ion-pair chromatography, as shown in
Fig. 1, chromatogram A. A typical chromatogram of saliva
samples from APL patients undergoing arsenic treatment is
shown in Fig. 1, chromatogram B. These results demon-
strated that AsIII, MMAIII, DMAV, MMAV, AsV, and
MMMTAV were detectable in the saliva of APL patients.
The presence of MMAIII and MMMTAV in human saliva
has not been reported in previous studies.
To confirm the presence of MMAIII and MMMTAV in the
saliva of APL patients, we analyzed the saliva samples
spiked with authentic standards of MMAIII or MMMTAV.
Figure 2 shows a comparison of the chromatograms of the
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original sample and the same sample spiked with authentic
standards. The spiked MMAIII or MMMTAV standard was
co-eluted with suspected compounds, giving rise to a dis-
tinct increase in the intensity of peak corresponding to
MMAIII or MMMTAV. The MMMTAV and MMAIII stand-
ards are not stable. MMMTAV can decompose easily into
MMAIII, and thereafter MMAIII can be oxidized to MMAV.
Even when stored at −80 °C after synthesis, MMMTAV still
can produce some MMAIII and MMAV during the thawing
process. Thus, spiking of MMMTAV also increased the
intensities of the peaks of MMAIII and MMAV (Fig. 2,
chromatograms B). Because MMAIII, MMAV, and
MMMTAV were well resolved in the chromatogram, these
spiking experiments could still demonstrate the existence of
MMAIII and MMMTAV in the saliva of APL patients. The
chromatographic fraction containing MMAIII was also col-
lected and treated with hydrogen peroxide (H2O2) to render
the oxidation of MMAIII to MMAV. As demonstrated in
Fig. 3, detection of MMAV in an H2O2-pretreated MMA
III-
containing chromatographic fraction provided further evi-
dence that MMAIII was present in the saliva of APL
patients.
ESI-MS/MS can provide information on the chemical
structures of the compounds; therefore, an HPLC-ESI-
MS/MS method was developed for the identification of
MMMTAV. Unfortunately, the concentration of MMMTAV
in the saliva of APL patients was below the detection limit
of ESI-MS/MS. Nevertheless, the authenticity of the syn-
thesized MMMTAV standard used was confirmed using the
ESI-MS/MS method. As shown in Fig. 4, the peaks repre-
senting characteristic ion transitions of MMMTAV (155/107,
155/121, and 155/137) were superimposed, which demon-
strated the authenticity of the MMMTAV standard synthe-
sized in our laboratory.
The results for MMAIII and MMMTAV in the saliva of
APL patients are summarized in Table 2. MMAIII and
MMMTAV were detected in 49 % and 22 % of saliva
samples from APL patients, respectively. The mean concen-
tration of MMAIII in all detectable saliva samples was
1.4 ng/mL, and the mean concentration of MMMTAV was
3.6 ng/mL. MMAIII and MMMTAVaccounted for 2.2 % and
4.0 % of total arsenic in the saliva of APL patients, respec-
tively. Table 3 shows the concentrations of MMAIII and
MMMTAV in the saliva of each of the APL patients.
MMAIII was detected in saliva samples from each of the
APL patients. However, MMMTAV was only found in the
saliva of patients 3, 7, and 8. The mean concentrations of


















Fig. 1 Typical chromatograms of arsenic standards (A) and saliva
samples (B) from acute promyelocytic leukemia (APL) patients. Sep-
aration was achieved using a reversed-phase ODS-3 column, and a
mobile phase comprising 5 mM tetrabutylammonium, 3 mM malonic
acid, and 5 % methanol (pH 5.65). Arsenic was detected at m/z 75
using an Agilent 7500ce inductively coupled plasma mass spectrome-
try (ICPMS) instrument with an octopole reaction system. Peaks 1–
8 correspond to AsIII, monomethylarsonous acid (MMAIII), dimethy-
larsinic acid (DMAV), monomethylarsonic acid (MMAV), dimethylmo-
nothioarsonic acid, dimethylarsinous acid (DMAIII), AsV, and
monomethylmonothioarsonic acid (MMMTAV), respectively
Retention time  (min)
2
A





Fig. 2 Chromatograms of saliva samples and the same samples spiked
with authentic arsenic standards. Peak identities and high-performance
liquid chromatography (HPLC)–ICPMS conditions were the same as
those for Fig. 1. A chromatograms were obtained from a saliva sample
(solid trace) and the same sample spiked with authentic MMAIII
(dashed trace). B chromatograms were obtained from a saliva sample
(solid trace) and the same sample spiked with MMMTAV (dashed
trace)
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MMAIII and MMMTAV differed among the APL patients.
The saliva of patient 8 contained the highest concentrations
of MMAIII (1.9 ± 0.6 ng/mL) and MMMTAV (5.3 ±
2.9 ng/mL) among all patients.
AsIII, DMAV, MMAV, and AsV
The results for AsIII, DMAV, MMAV, and AsV in saliva
samples from APL patients are also shown in Table 2. AsIII,
DMAV, MMAV, and AsV were detectable in 98 % of saliva
samples. The mean concentration was 39.1 ng/mL for AsIII,
9.2 ng/mL for AsV, 1.0 ng/mL for DMAV, and 2.0 ng/mL for
MMAV. The summed concentration of all arsenicals in the
saliva ranged from 0.1 to 210.1 ng/mL, with a mean con-
centration of 52.2 ng/mL. AsIII was the predominant species
in the saliva of APL patients, and accounted for 71.8 % of
arsenic in the saliva.
The arsenic concentration was low in two saliva samples
collected from patients 1 and 4 before the first arsenic
injection (Table 3). The saliva of patient 1 contained only
0.3 ng/mL AsIII, and the saliva of patient 4 contained
0.1 ng/mL DMAVand 0.1 ng/mL AsV. The rest of the saliva
samples were collected after the first infusion of arsenic, and
the concentrations of arsenic were much higher than in the
samples collected before any infusion of arsenic. AsIII,
DMAV, MMAV, and AsV were detected in all saliva samples
collected after the first infusion of arsenic, and AsIII was
consistently the predominant arsenic species in the saliva of
all patients. Although the same dose of arsenic trioxide was
administered to all APL patients, the mean concentrations of
arsenicals differed among individual APL patients. Patients
2, 3, 7, and 8 had higher concentrations of arsenic in the
saliva compared with the other patients.
Temporal profiles of common arsenic species
Figure 5 shows the temporal profiles of four common arse-
nic species (AsIII, DMAV, MMAV, and AsV) and their sum in
the saliva of patients 4 and 6. Before the study, patient 4 did
not receive an arsenic injection, but arsenic was adminis-
tered to patient 6 (relapsed) for 11 days. Saliva samples were
consecutively collected for 72 h from patient 4 (Fig. 5a) and
for 52 h from patient 6 (Fig. 5b). Three infusions of arsenic
were administered to patient 4 during the sample collection
period, and two infusions were administered to patient 6.
The interval between arsenic infusions was 24 h. As shown
in Fig. 5a, the arsenic concentration was low in the saliva
sample of patient 4 before arsenic infusion. Following the
first arsenic infusion, the concentrations of arsenicals in the
saliva increased immediately, and decreased thereafter. The
profiles were similar following the second and third infu-
sions. Nevertheless, the overall level of arsenic in the saliva
increased with the progression of arsenic treatment, indicat-
ing that arsenic had accumulated in the body of patient 4.
Compared with patient 4, the background arsenic concen-
tration in the first saliva sample of patient 6 (Fig. 5b) was
higher because arsenic trioxide had been administered to
this patient 11 times over 11 days prior to the study. The
arsenic concentration in the saliva of patient 6 showed a
delayed increase in response to arsenic infusion, and similar
patterns of changes in the two subsequent monitoring
cycles.
Temporal profiles of percentages of methylated arsenicals
in the saliva of patients 4 and 6 are presented in Fig. 6.




Fig. 3 A chromatogram obtained from HPLC–ICPMS analysis of an
H2O2-treated chromatographic fraction containing MMA
III. Peak iden-
tities and HPLC–ICPMS conditions are the same as those for Fig. 1





Fig. 4 Chromatogram obtained from HPLC–electrospray ionization
tandem mass spectrometry (ESI-MS/MS) analysis of synthesized
MMMTAV standard. Anion-exchange separation was performed using
a Hamilton PRP-X100 column and a mobile phase comprising 50 %
methanol and 5 mM ammonium formate (pH 6). ESI-MS/MS was
performed in multiple reaction monitoring mode. Three characteristic
ion transitions, 155/107, 155/121, and 155/137, of MMMTAV were
monitored simultaneously
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Following arsenic infusion, the percentages of MMAV,
DMAV, and their sum decreased in the saliva of both
patients, suggesting that the methylation efficiency of AsIII
was inhibited by accumulating AsIII. However, there was a
difference in the temporal profiles of the percentages of
salivary arsenicals between patients 4 and 6. The percentage
of methylated arsenicals in the saliva of patient 4 declined
continuously from 35 % to 6 %, as shown in Fig. 6a. For
patient 6, the percentages of methylated arsenicals decreased
immediately following arsenic infusion, and increased
thereafter (Fig. 6b). A comparably similar profile between
the two patients was repeated only after the second infusion.
Discussion
Following arsenic trioxide administration, a portion of AsIII
can be transformed into methylated arsenicals in the body of
APL patients through the processes of biological methylation
[19, 41]. Salivary glands have high blood flow, and chemicals
and their metabolites in blood can be distributed in saliva
through passive diffusion, active transport, and ultrafiltration
[42–45]. Our previous efforts showed that AsIII and its metab-
olites are present in saliva in populations who were chronical-
ly exposed to arsenic via drinking water or from chromated
copper arsenate treated wood in playgrounds [23–25]. No
attention has been paid to arsenic speciation in human saliva
in clinical settings, in which APL patients were acutely ex-
posed to high doses of AsIII via intravenous infusion.
Most arsenic in the saliva of APL patients was detected
as AsIII. MMAV and DMAV, metabolites of AsIII commonly
found in human urine [15, 16, 20–26], were also detected in
saliva of APL patients. As important intermediates in the
transformation processes of AsIII, MMAIII and DMAIII were
found in human urine in previous studies [15, 27–29]. Our
present study demonstrates the presence of MMAIII in the
saliva of APL patients who received a high dose of AsIII,
which provides additional evidence of biomethylation of
Table 2 Summary of arsenic
species in saliva samples col-
lected from APL patients
ND not detectable, DMAV dime-


















over sum of all
species
Mean Range
AsIII 39.1 0.3–181.5 106 98 72.4 0–100
AsV 9.2 ND to 84.6 106 98 18.7 0–72.0
DMAV 1.0 ND to 5.2 106 98 3.0 0–34.7
MMAV 2.0 ND to 7.3 106 98 4.8 0–17.9
MMAIII 1.4 ND to 4.8 53 49 2.2 0–4.1
MMMTAV 3.6 ND to 10.6 24 22 4.0 0–9.2
Sum of all species 52.2 0.1–210.1
Table 3 Summary of arsenic species in saliva samples from individual APL patients






Concentrations of arsenic species (ng/mL) [mean ± SD (n)]
AsIII DMAV MMAV AsV MMAIII MMMTAV
Before 1 1 0.3 ND ND ND ND ND
4 1 ND 0.1 ND 0.1 ND ND
After 1 18 12.1±9.0 0.7±0.5 1.3±0.9 3.7±3.1 0.6±0.2 (2) ND
2 9 57.4±17.7 1.3±0.5 4.3±2.0 5.1±1.8 1.3±0.3 (9) ND
3 7 59.1±23.2 0.5±0.1 2.3 ±0.6 13.9±9.0 1.6±0.5 (4) 2.9±1.6 (7)
4 9 20.1±25.1 0.6±0.4 0.9±0.6 2.8±2.2 0.7±0.6 (6) ND
5 20 27.0±11.3 0.7±0.3 1.7±0.8 13.8±9.8 0.4±0.1 (3) ND
6 16 35.5±17.0 1.8±1.0 1.8±1.1 3.2±2.5 1.3±0.7 (14) ND
7 6 96.9±46.3 1.2±0.6 1.4±0.7 6.3±5.4 2.7±1.5 (4) 1.0±0.5 (5)
8 11 64.7±20.1 0.9±0.2 2.9±1.2 15.7±7.4 1.9±0.6 (10) 5.3±2.9 (11)
9 10 45.2±18.9 1.7±1.4 2.1±1.3 21.4±22.9 0.8 (1) 1.6 (1)
ND not detectable, SD standard deviation, n number of samples in which MMAIII and MMMTAV were detected
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AsIII in the human body. The cytotoxicity and genotoxicity
of MMAIII were shown to be greater than those of inorganic
arsenic and pentavalent methylated arsenicals [12, 32–35]
Thiolated methylated arsenicals have recently been identi-
fied as arsenic metabolites in human urine and nails [30, 31].
The present study also shows the presence ofMMMTAVin the
saliva of APL patients (patients 3, 7, and 8) undergoing
arsenic treatment. Little is known about how these thiolated
metabolites of arsenic are produced in the human body. Pre-
vious studies demonstrated that thiolated arsenicals may be
produced in the gastrointestinal tract of rats by intestinal flora
[46, 47]. However, in our study arsenic was administered to
APL patients via intravenous infusion, and it was unlikely that
MMMTAV in the saliva of APL patients was produced in the
gastrointestinal tract. Thiolated arsenicals could probably be
formed using H2S produced from enzymatically catalyzed
reactions in mammalian cells [48, 49]. Thiolated methylated
arsenicals were shown to be more toxic than their oxygen-
containing analogs and exhibited toxicity comparable to that
of trivalent arsenicals [30, 36–38].
Most arsenic infused is excreted from the bodies of APL
patients through urine [15, 50]. The temporal profiles of
salivary arsenicals depicted in our present study might well
indicate the overall process of arsenic infusion, metabolism,
and tributary excretion from the body. Arsenic accumulated
in the saliva of patient 4 in the initial stage of treatment, but
in the saliva of patient 6 the arsenic concentration
reached a steady state after the adaptation to arsenic
treatment. Likewise, a steady state was also reached in
the urine within 5 days after repeated ingestion of 125–
1,000 μg AsIII daily [50].
























































Fig. 5 Temporal profiles showing the concentrations of arsenic spe-
cies in the saliva of APL patients. The patients received an intravenous
infusion of a 10 mg dose of arsenic trioxide daily. The arrows indicate
the time at which the infusion started. Collection of saliva samples
from patient 4 (a) lasted 72 h with three arsenic (AsIII) administrations
of long infusion duration (about 18 h), and saliva samples from patient
6 (b) were collected for 52 h with two administrations of short infusion
duration (below 4 h). Squares AsIII, circles DMAV, upright triangles
MMAV, inverted triangles AsV, diamonds sum of arsenic species































Fig. 6 Temporal profiles showing the percentages of methylated
arsenicals in the saliva of APL patient 4 (a) and patient 6 (b). The
procedures for arsenic administration were the same as described for
Fig. 5. Triangles MMAV, circles DMAV, diamonds sum of methylated
arsenic
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Many efforts have been made to understand whether high
doses of ingested AsIII can affect methylation of arsenic in the
living body. It was demonstrated that the formation of DMAV
could be effectively inhibited by heavy ingestion of AsIII [51,
52]. Compared with the general population, APL patients who
received high doses of AsIII intravenously had a lower fraction
of DMAV in their urine [15], an observation that was sup-
ported by the saliva analysis in the present study. Methylated
arsenicals accounted for 24 % of arsenic in the saliva of a
general population chronically exposed to arsenic in drinking
water [23]. In contrast, the percentage ofmethylated arsenicals
in the saliva of APL patients was only 7.8 %. Additionally, the
percentage of methylated arsenicals in the saliva of APL
patients significantly decreased following each AsIII infusion,
reflecting possible saturation of arsenic methylation by the
high levels of AsIII in the body of APL patients.
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